9:30 am Leveraging Noninvasive Markers of Fibrosis Alongside Serial-Biopsy Clinical Studies of Efruxifermin to Elucidate Breadth of Response Across Advanced Fibrosis & Cirrhosis Due to MASH
Time: 9:30 am
day: Conference Day 2
Details:
- Characterization of disease progression in untreated patients through longitudinal assessments in long-term studies
- Rapid and sustained effects of efruxifermin on fibrotic pathways to arrest progression and reverse fibrosis in MASH patients with advanced fibrosis and compensated cirrhosis
- Corroboration of improved liver health and underlying disease drivers as assessed by multiple measures of liver injury, fibrosis, and metabolic parameters
